Effect of polyunsaturated phosphatidylcholine on lipid structure and cAMP-dependent signal transduction in the liver of rats chronically intoxicated with ethanol

Lipid Replacement Therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function

Lipid Replacement Therapy, the use of functional oral supplements containing cell membrane phospholipids and antioxidants, has been used to replace damaged, usually oxidized, membrane glycerophospholipids that accumulate during aging and in various clinical conditions in order to restore cellular function. This approach differs from other dietary and intravenous phospholipid interventions in the composition of phospholipids and their defense against oxidation during storage, ingestion, digestion and uptake as well as the use of protective molecules that noncovalently complex with phospholipid micelles and prevent their enzymatic and bile disruption. Once the phospholipids have been taken in by transport processes, they are protected by several natural mechanisms involving lipid receptors, transport and carrier molecules and circulating cells and lipoproteins until their delivery to tissues and cells where they can again be transferred to intracellular membranes by specific and nonspecific transport systems. Once delivered to membrane sites, they naturally replace and stimulate removal of damaged membrane lipids. Various chronic clinical conditions are characterized by membrane damage, mainly oxidative but also enzymatic, resulting in loss of cellular function. This is readily apparent in mitochondrial inner membranes where oxidative damage to phospholipids like cardiolipin and other molecules results in loss of trans-membrane potential, electron transport function and generation of high-energy molecules. Recent clinical trials have shown the benefits of Lipid Replacement Therapy in restoring mitochondrial function and reducing fatigue in aged subjects and patients with a variety of clinical diagnoses that are characterized by loss of mitochondrial function and include fatigue as a major symptom. This Article is Part of a Special Issue Entitled: Membrane Structure and Function: Relevance in the Cell's Physiology, Pathology and Therapy.

Reversal of experimental ethanol-induced liver steatosis by borage oil

The aim of study was to evaluate the hepatoprotective effect of borage oil containing predominantly gamma-linolenic acid in rats with alcoholic steatohepatitis. Liver of ethanol-treated animals was characterized by fatty and hydropic dystrophies. Liver triglyceride contents and activitiies of serum marker enzymes were significantly increased. Ethanol increased nicotinamide adenine dinucleotide phosphate hydrogen (NADPH)-induced chemiluminescence and the contents of liver thiobarbituric acid reactive substances (TBARS). The reduced glutathione content in the liver was decreased. Ethanol enhanced liver microsomal cytochrome P-450 (CYP450) content, aniline p-hydroxylase and amydopyrine-N-demethylase activities. The treatment with borage oil improved the liver morphology, decreased triglyceride contents and normalized serum marker enzyme activities. Borage oil developed an antioxidant effect in ethanol-treated rats. The treatment with this compound decreased NADPH-induced chemiluminescence and the content of lipid peroxidation products. Borage oil normalized CYP450 content compared with the ethanol-treated group. CYPI450 2E1 isoform is a main source of free oxygen radicals in the liver of ethanol-treated rats and we propose that the antioxidant effect of borage oil is realized via the normalization of CYP450 content and activities of CYP450-related microsomal oxidases, as borage oil can improve the lipid surrounding of CYP450. In our opinion, the hepatoprotection by borage oil in alcoholic steatosis is connected with its antioxidant properties.

Cytoprotective effects of polyenoylphosphatidylcholine (PPC) on beta-cells during diabetic induction by streptozotocin

Polyenoylphosphatidylcholine (PPC), a phosphatidylcholine-rich phospholipid extracted from soybean, has been reported to protect liver cells from alloxan-induced cytotoxicity. The present study aimed to investigate whether PPC protects pancreatic beta-cells from the cytotoxic injury induced by streptozotocin, thus preserving insulin synthesis and secretion. beta-Cells of the PPC-treated rats showed a significant reduction of cell death with lesser destruction of plasma membrane on streptozotocin insult. They demonstrated a rapid recovery of GLUT-2 expression, whereas almost irreversible depletion of membrane-bound GLUT-2 was seen in beta-cells of the rats treated with only streptozotocin. A similar cytoprotective effect of PPC was also monitored in the PPC-pretreated MIN6 cells. These beta-cells retained their ability to synthesize and secrete insulin and no alteration of glucose metabolism was detected. These results strongly suggest that PPC plays important roles not only in protecting beta-cells against cytotoxicity but also in maintaining their insulin synthesis and secretion for normal glucose homeostasis.

Effects of soybean diet on the beta cells in the streptozotocin treated rats for induction of diabetes

Certain dietary components have been reported to potentially suppress the initiation of experimental insulin-dependent diabetes mellitus (IDDM) in animal models. In the present study, we showed that dietary soybean prevents induction of experimental hyperglycemia by retaining beta cell activity. In rats fed raw soybean, expression of insulin mRNA in pancreatic beta cells was significantly increased compared to those fed with normal diet. In those rats and upon injection of streptozotocin, only few beta cells underwent cell death, most of them demonstrating active viability with enhanced mRNA expression and insulin content. This is consistent with the fact that blood glucose level was normalized (72.51 +/- 1.54 mg/dl) after a transitory hyperglycemic state (> 300 mg/dl). It implies the dietary soybean can prevent beta cell injury by streptozotocin. Moreover, a prolonged hyperglycemia was not observed in rats fed raw soybean even when this was substituted by the normal diet after streptozotocin injection. In contrast, in streptozotocin-treated rats fed normal diet, most beta cells were destroyed and severe hyperglycemia was observed. Although the protective effect was not recorded in the rats fed with heated soybean, some beta cells were found to retain their cell organelles for insulin secretion indicating that some heat-stable components of soybean might prevent the cytotoxic insult. Therefore, we suggest that dietary soybean protected the streptozotocin-induced beta cell damage and restrained the development of hyperglycemia in rats.

Antioxidative effect of prostaglandin E2 in thioacetamide-induced liver cirrhosis

Several studies provided evidence that various prostaglandins exhibited a hepatoprotective effect in vivo as well in vitro the mechanism of which is still in debate. Therefore, the aim of our studies was to examine the effect of PGE2 on some biochemical and morphological alterations in chemically induced liver cirrhosis in rats. A micronodular liver cirrhosis was induced by treatment of rats with thioacetamide for 3 months. Morphologically, the administration of PGE2 for 8 days reduced the extent of vacuolar transformation of the hepatocytes and the density of the nuclear structure without affecting the fibrotic state as assessed by the hepatic hydroxyproline content. The widening of the sinusoids indicated an improved hepatic microcirculation. Administration of PGE2 significantly elevated the percentage portion of arachidonic (20:4) and docosapentaenoic (22:5) acid in the hepatic phospholipids and reduced the ratio 20:3/20:4 fatty acids in comparison to the untreated cirrhotic animals. The hepatic MDA concentration was decreased by 40% in PGE2-treated animals. PGE2 treatment also reduced the content of polar as well as of non-polar carbonyls when compared with the controls. Moreover, treatment with PGE2 lowered iron-induced or iron plus ascorbate-induced MDA production of isolated hepatocytes. From the data it was concluded that the hepatoprotective effect of PGE2 may be related to its antioxidative capacity.

Hepatic and pancreatic effects of polyenoylphosphatidylcholine in rats with alloxan-induced diabetes

Polyenoylphosphatidylcholine (PPC: 100 or 300 mg kg-1 b.w., by gastric intubation for 30 days) produced a clearcut protection of the liver of rats treated with alloxan (150 mg kg-1 b.w., i.p.). The liver of rats treated with alloxan was characterized by hydropic dystrophy and lymphocytic infiltrations. Treatment with alloxan increased serum gamma-GT and ALAT activities. The liver structure of rats treated with PPC did not differ from the liver of control animals. PPC normalized the biochemical abnormalities caused by the diabetes. The number of pancreatic islets and beta/alpha cell ratio decreased in the diabetic rats. A number of beta-cells in this group did not contain granules. PPC prevented the decrease in the number of islets and the beta/alpha cell ratio in the pancreas of the diabetic rats. The intensity of staining of beta-cell granules in the pancreas of PPC-treated rats had a position intermediate between the control and diabetic groups. Alloxan increased the blood glucose content where treatment with PPC decreased this. The results suggest that PPC acts as a cytoprotector in the liver and pancreas of rats with experimental diabetes induced by alloxan.